SpeciCare

SpeciCare is a private, early-stage company revolutionizing cancer care through its proprietary Live Tissue Science™ platform, which involves the collection, cryopreservation, and banking of live tumor tissue. This service model allows patients to retain ownership of their tissue, facilitating access to personalized medicine approaches like ex vivo drug testing, organoid creation, and clinical vaccine development outside of standard clinical pathways. Founded by surgical oncologist Dr. Ken Dixon, the company targets a significant gap in oncology by ensuring preserved tissue is available for future, evolving diagnostics and therapies, positioning itself as a patient-centric service in the precision medicine landscape. Its business appears to be service-based and likely pre-revenue or early revenue, focusing on building a biobank and partnering with researchers and clinicians.

Live Tissue Science™ (LTS™): A service platform for the cryopreservation and biobanking of live, viable tumor tissue and blood to enable future advanced testing, personalized therapy development (e.g., vaccines, organoids), ex vivo drug testing, and clinical trial access.

SpeciCare operates in a niche with few direct competitors offering live tissue cryopreservation directly to patients. Indirect competition includes traditional tissue biobanks (often research-focused), large clinical labs (LabCorp, Quest) that handle FFPE tissue, and academic medical centers with internal protocols. Its patient-ownership and portability focus is a key differentiator.